Aug 24, 2016 ... Expert Report of John Fiddes, Ph.D., Bristol-Myers Squibb. Company v. ...
Goeddel, D.V., et al., Expression in Escherichia coli of chemically ... Declaration
of Julie L. Davis, Sanofi-Aventis U.S. LLC v. Genentech, Inc.
"Action" means State ofAlabama, et al v. Bristol-Myers Squibb, et al., MDL No.
1413. (S.D.N.Y.). BB. "Releasers" means Plaintiff States, and the Settling
Hood, ex rel. Mississippi v. Bristol-Myers Squibb Company, Sanofi-Aventis, et al.
... U.S. Chamber Amicus Brief - Hood ex rel Mississippi v. BMS, Sanofi, et al.
Nov 10 2016, Brief amici curiae of Washington Legal Foundation, et al. filed. ...
Dec 20 2016, Reply of petitioner Bristol-Myers Squibb Company filed.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail ...
Jun 16, 2016 ... *P < 0.05 by Mann-Whitney test vs. unstimulated B cells (Unstim) (G–I). ..... Tipton
et al. described in SLE patients a population of activated naive B cells .... with
human CD40LG (hCD40L-CHO cells) at Bristol-Myers Squibb. .... D. Stetsko, F.
Casano, S. Kansal, P.M. Davis, J. Carman, C.K. Zhang, S.G. Nadler, ....